Company
Epiliquid
We are not building one cancer test. We are building the platform architecture that transforms epigenetic biomarkers into blood-based molecular tests.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Delaware, United States
- Founded
- 2021
- Customers
- clinical partners, laboratory networks
Claim, correct or request removal
Record updated 18 September 2026
About
Our proprietary technology platform integrates AI-driven biomarker discovery, patented assay architecture, proprietary probe design, and PCR-compatible implementation into one scalable system.
Loading relationship preview